ABI-009 (Nab-rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03463265 |
Recruitment Status :
Active, not recruiting
First Posted : March 13, 2018
Last Update Posted : June 14, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma | Drug: ABI-009 Drug: Bevacizumab Drug: Temozolomide Drug: Lomustine Radiation: Radiation Drug: Marizomib | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 56 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2, Open-label Study of ABI-009 (Nab-Rapamycin) in Patients With Recurrent High-grade Glioma and Patients With Newly Diagnosed Glioblastoma |
Actual Study Start Date : | August 1, 2018 |
Estimated Primary Completion Date : | December 2022 |
Estimated Study Completion Date : | December 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: ABI-009 |
Drug: ABI-009
ABI-009 as single agent or in combination with other agents
Other Name: nab-rapamycin, nanoparticle albumin-bound rapamycin |
Experimental: ABI-009 + bevacizumab |
Drug: ABI-009
ABI-009 as single agent or in combination with other agents
Other Name: nab-rapamycin, nanoparticle albumin-bound rapamycin Drug: Bevacizumab bevacizumab |
Experimental: ABI-009 + temozolomide |
Drug: ABI-009
ABI-009 as single agent or in combination with other agents
Other Name: nab-rapamycin, nanoparticle albumin-bound rapamycin Drug: Temozolomide temozolomide |
Experimental: ABI-009 + lomustine |
Drug: ABI-009
ABI-009 as single agent or in combination with other agents
Other Name: nab-rapamycin, nanoparticle albumin-bound rapamycin Drug: Lomustine lomustine |
Experimental: ABI-009 + temozolomide + radiotherapy |
Drug: ABI-009
ABI-009 as single agent or in combination with other agents
Other Name: nab-rapamycin, nanoparticle albumin-bound rapamycin Drug: Temozolomide temozolomide Radiation: Radiation radiation |
Experimental: ABI-009 + marizomib |
Drug: ABI-009
ABI-009 as single agent or in combination with other agents
Other Name: nab-rapamycin, nanoparticle albumin-bound rapamycin Drug: Marizomib marizomib |
- objective overall response rate according to RANO 2010 criteria [ Time Frame: 12 months ]
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 12 months ]
- progression free survival [ Time Frame: 12 months ]
- overall survival [ Time Frame: 12 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria Specific for Arm A
- All subjects must have histologic evidence of high grade glioma (World Health Organization [WHO] grade 3 or grade 4) and radiographic evidence of recurrence or disease progression (defined as either a greater than 25% increase in the largest bi-dimensional product of enhancement, a new enhancing lesion, or a significant increase in T2 FLAIR). Subjects must have at least 1 measurable lesion by RANO criteria (≥ 10 mm in 2 perpendicular diameters).
- Patients must have previously failed a treatment regimen, including radiation and/or chemotherapy.
- No prior treatment with mTOR inhibitors.
- No prior treatment with temozolomide for the treatment of recurrent glioma for patients entering the ABI-009 + temozolomide cohort.
- No prior treatment with bevacizumab or any other anti-angiogenic agents, including sorafenib, sunitinib, axitinib, pazopanib, or cilengitide for the ABI-009 + bevacizumab arm.
- No prior treatment with lomustine for the ABI-009 + lomustine arm.
- No prior treatment with marizomib or any other proteasome inhibitors, including bortezomib, carfilzomib, or ixazomib, for patients entering the ABI-009 + marizomib cohort.
- At least 4 weeks from surgical resection and at least 12 weeks from the end of radiotherapy prior to enrollment in this study, unless relapse is confirmed by tumor biopsy or new lesion outside of radiation field, or if there are two MRIs confirming progressive disease that are approximately 4 weeks apart.
Inclusion Criteria Specific for Arm B
- Histologically confirmed newly diagnosed glioblastoma.
- Patients must have had surgery and can have either non-measurable disease or a measurable post-contrast lesion after surgery detected by MRI.
- No prior treatment with mTOR inhibitors, and no prior local or systemic therapy for GBM.
Exclusion Criteria Common for Both Arms A and B
A patient will not be eligible for inclusion in this study if any of the following criteria apply:
- Co-medication or concomitant therapy that may interfere with study results, including anti-coagulants and enzyme-inducing anti-epileptic drugs (EIAEDs).
- History of thrombotic or hemorrhagic stroke or myocardial infarction within 6 months.
- Pregnant or breast feeding.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics & psychiatric illness/social situations that would limit compliance with study requirements, or disorders associated with significant immunocompromised state.
- Active gastrointestinal bleeding.
- Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥90 mm Hg.
- Patients with history of intestinal perforations, fistula, hemorrhages and/or hemoptysis ≤6 months prior to first study treatment.
- Uncontrolled diabetes mellitus as defined by HbA1c >8% despite adequate therapy.
- Patients with history of interstitial lung disease and/or pneumonitis, or pulmonary hypertension.
- Use of strong inhibitors and inducers of CYP3A4 within the 14 days prior to receiving the first dose of ABI-009. Additionally, use of any known CYP3A4 substrates with narrow therapeutic window (such as fentanyl, alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, terfanide) within the 14 days prior to receiving the first dose of ABI-009.
- Known other previous/current malignancy requiring treatment within ≤ 3 years except for limited disease treated with curative intent, such as in situ prostate cancer, intracapsular renal cancer, cervical carcinoma in situ, squamous or basal cell skin carcinoma, and superficial bladder carcinoma.
- Any comorbid condition that restricts the use of study drug and confounds the ability to interpret data from the study as judged by the Investigator or Medical Monitor.
- Known Human Immunodeficiency Virus (HIV), or active Hepatitis B or Hepatitis C.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03463265
United States, California | |
St. Joseph Heritage Healthcare | |
Fullerton, California, United States, 92835 | |
Hoag Memorial Hospital Presbyterian | |
Newport Beach, California, United States, 92663 | |
John Wayne Cancer Institute | |
Santa Monica, California, United States, 90404 |
Responsible Party: | Aadi Bioscience, Inc. |
ClinicalTrials.gov Identifier: | NCT03463265 |
Other Study ID Numbers: |
GBM007 |
First Posted: | March 13, 2018 Key Record Dates |
Last Update Posted: | June 14, 2022 |
Last Verified: | June 2022 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Glioblastoma Glioma Astrocytoma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Sirolimus Bevacizumab Temozolomide Lomustine Antineoplastic Agents, Immunological |
Antineoplastic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Anti-Bacterial Agents Anti-Infective Agents Antibiotics, Antineoplastic Antifungal Agents Immunosuppressive Agents Immunologic Factors |